MUCOBOOST

France
|
2025-2028
  • Adults (18-64 years)
  • General population
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Vaccination

Levy

France
|
2024-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Vaccination

Ylä-Herttuala

Finland
|
2026-2026
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Vaccination

Ziegler

Austria Belgium Germany Sweden United Kingdom
|
2024-2027
  • Infants (<1 year)
  • Fragile population
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Vaccination

Bezzarga

Turkey
|
2024-2025
  • Adults (18-64 years)
  • General population
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Non pharmacological intervention
  • Essential Oils

Pfizer C5091018

Argentina Belgium Brazil Denmark France Germany Greece Japan Mexico Netherlands Puerto Rico Slovakia South Korea Spain Sweden Taiwan Türkiye United States of America
|
2025-2028
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Immunocompromised patients
  • Hospital
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir
  • Ibuzatrelvir

Sarno

Spain
|
2024-2026
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Influenza A
  • Influenza B
  • Pharmacological intervention
  • Immunomodulator
  • PRS CK STORM

DisCoVeRy

Austria Belgium France Greece Luxembourg Norway Portugal
|
2020-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Remdesivir
  • Tixagevimab/Cilgavimab
  • Hydroxychloroquine
  • Interferon Beta-1A
  • Lopinavir/ritonavir

INVENT

United Kingdom United States
|
2025-2026
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Immunocompromised patients
  • Hospital
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Adenovirus
  • Rhinovirus
  • Human metapneumovirus
  • Parainfluenza Virus
  • Pharmacological intervention
  • Antivirals
  • SNG001

COV2NOSE

Finland
|
2025-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Vaccination
  • Nasal vaccine

Grimberg

Israel
|
2024-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Apo-Si-K170A-C76

Borys

Poland
|
2024-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Non pharmacological intervention
  • Rehabilitation
  • Education